Journal
BLOOD REVIEWS
Volume 45, Issue -, Pages -Publisher
CHURCHILL LIVINGSTONE
DOI: 10.1016/j.blre.2020.100709
Keywords
Acute myeloid leukemia; Myelodysplastic syndromes; Immune checkpoint inhibition; TIM-3; CD47; Leukemic stem cells
Categories
Funding
- NCI's Cancer Clinical Investigator Team Leadership Award (CCITLA)
- Dennis Cooper Hematology Young Investigator Award
- National Cancer Institute of the National Institutes of Health [P30 CA016359]
Ask authors/readers for more resources
Immune checkpoint inhibitors have shown mixed results in clinical trials in patients with acute myeloid leukemia and myelodysplastic syndromes, but there is optimism for the future of this field. Advances in understanding the immunologic landscape, potential biomarkers, and resistance mechanisms provide hope, but challenges such as the lack of validated biomarkers and the development of safe combination therapies still need to be addressed.
Immune checkpoint inhibitors (ICI) have yielded mixed but largely underwhelming results in clinical trials in patients with acute myeloid leukemia and myelodysplastic syndromes to date. However, increasing under standing of the immunologic landscape, potential biomarkers for benefits, and mechanisms of resistance, as well as the use of rational combinations, and identification of novel targets leaves plenty of room for optimism. Herein, we review recent advances in the preclinical and clinical development of ICI therapy in patients with myeloid malignancies and explore some of the important challenges facing the field such as the absence of validated biomarkers, the development of synergistic and safe combination therapies, and efforts to determine the best setting of ICI along the disease course. We finally foresee the future of the field and propose solutions to some of the major beforementioned obstacles.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available